Beneficial Effect of Phosphodiesterase-5 Inhibitor in Experimental Inflammatory Bowel Disease; Molecular Evidence for Involvement of Oxidative Stress

REFERENCES

• Abdollahi M., Bahreini-Moghadam A., Emami B., Fooladian F., Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp. Biochem. Physio. C. Toxicol. Pharmacol. 2003b; 135: 331–336
   Web of Science ®Google Scholar
• Abdollahi M., Chan T. S., Subrahmanyam V., O'Brien P. J. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol. Cell. Biochem. 2003a; 252: 205–211
   PubMed Web of Science ®Google Scholar
• Abdollahi M., Fooladian F., Emami B., Zafari K., Bahreini-Moghadam A. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum. Exp. Toxicol. 2003c; 22: 587–592
   PubMed Web of Science ®Google Scholar
• Abdollahi M., Ranjbar A., Shadnia S., Nikfar S., Rezaiee A. Pesticides and oxidative stress. Med. Sci. Monit. 2004; 10: RA144–RA147
   Web of Science ®Google Scholar
• Abdollahi M., Simaiee B. Stimulation by theophylline and sildenafil of rat submandibular secretion of protein, epidermal growth factor and flow rate. Pharmacol. Res. 2003; 48: 445–449
   PubMed Web of Science ®Google Scholar
• Aghababaeian R., Ghazi-Khansari M., Abdi K., Taghadosinejad F., Abdollahi M. Protective effects of sildenafil and dipyridamol from lead-induced lipid peroxidation in perfused rat liver. Intl. J. Pharmaol. 2005; 1: 157–160
   Google Scholar
• Ahnfelt-Ronne I., Nielsen O. H. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. Agents. Actions. 1987; 21: 191–194
   PubMedGoogle Scholar
• Allgayer H. Clinical relevance of oxygen radicals in inflammatory bowel disease–facts and fashion. Klin. Wochenschr. Rev. 1991; 69: 1001–1003
   PubMedGoogle Scholar
• Arnhold J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry. (Mosc). 2004; 69: 4–9
   PubMed Web of Science ®Google Scholar
• Banner K. H., Trevethick M. A. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends. Pharmacol. Sci. Rev. 2004; 25: 430–436
   PubMed Web of Science ®Google Scholar
• Barbosa D. S., Cecchini R., El Kadri M. Z., Rodriguez M. A., Burini R. C., Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemente with fish oil omega-3 fatty acids. Nutrition 2003; 19: 837–842
   PubMed Web of Science ®Google Scholar
• Bortolotti M., Mari C., Lopilato C., La, Rovere L., Miglioli M. Sildenafil inhibits gastroduodenal motility. Aliment. Pharmacol. Ther. 2001; 15: 157–161
   PubMed Web of Science ®Google Scholar
• Dias-Junior C. A., Souza-Costa D. C., Zerbini T., da Rocha J. B., Gerlach R. F., Tanus-Santos J. E. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth. Analg. 2005; 101: 115–120
   PubMed Web of Science ®Google Scholar
• D'Odorico A., Bortolan S., Cardin R., D'Inca’ R., Martines D., Ferronato A., Sturniolo G. C. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 2001; 36: 1289–1294
   PubMed Web of Science ®Google Scholar
• Elson C. O., Cong Y., Brandwein S., Weaver C. T., McCabe R. P., Mahler M., Sundberg J. P., Leiter E. H. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann. N. Y. Acad. Sci. 1998; 859: 85–95
   PubMed Web of Science ®Google Scholar
• Elson C. O., Sartor R. B., Tennyson G.S., Riddell R. H. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344–1367
   PubMed Web of Science ®Google Scholar
• Ghafari H., Yasa N., Mohammadirad A., Minaie B., Zamani M. J., Nikfar S., Dehghan G. H., Khorasani R., Abdollahi M. Protection by Ziziphora Clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum. Exp. Toxicol. 2006; 25: 325–332
   PubMed Web of Science ®Google Scholar
• Ghazanfari G., Minaie B., Yasa N., Ashtaral-Nakhai L., Mohammadirad A., Nikfar S., Dehghan G., Shetab-Boushehri V., Jamshidi H., Khorasani R., Salehnia A., Abdollahi M. Biochemical and histopathological evidences for beneficial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol. Mech. Methods 2006; 16(7)365–372
   PubMed Web of Science ®Google Scholar
• Gibson P. R., Iser J. Inflammatory bowel disease. Aust. Fam. Physician 2005; 34: 233–237
   PubMedGoogle Scholar
• Grisham M. B. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994; 344: 859–861
   PubMed Web of Science ®Google Scholar
• Gupta R. C. Toxicology of Organophosphates and Carbamate Compounds, , et al. Elsevier Academic Press, San Diego 2006
   Google Scholar
• Hadjibabaie M., Rastkari N., Rezaie A., Abdollahi M. The adverse drug reaction in the gastrointestinal tract: an overview. Intl. J. Pharmacol. 2005; 1: 1–8
   Google Scholar
• Hatoum O. A., Miura H., Binion D. G. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. Heart. Circ. Physiol. Rev. 2003; 285: H1791–1796
   Web of Science ®Google Scholar
• Jagtap A. G., Shirke S. S., Phadke A. S. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J. Ethnopharmacol. 2004; 90: 195–204
   PubMed Web of Science ®Google Scholar
• Jahanshahi G., Motavasel V., Rezaie A., Hashtroudi A. A., Daryani N. E., Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci. 2004; 49: 1752–1757
   PubMed Web of Science ®Google Scholar
• Jeremy J. Y., Angelini G. D., Khan M., Mikhailidis D. P., Morgan R. J., Thompson C. S., Bruckdorfer K. R., Naseem K. M. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc. Res. Rev. 2000; 46: 50–54
   PubMed Web of Science ®Google Scholar
• Jurjus A. R., Khoury N. N., Reimund J. M. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 2004; 50: 81–92
   PubMedGoogle Scholar
• Katzung B. G. Basic & Clinical Pharmacology 8th edition. Appleton & Lange. 2000
   Google Scholar
• Koupparis A. J., Jeremy J. Y., Muzaffar S., Persad R., Shukla N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU. Int. 2005; 96: 423–427
   PubMed Web of Science ®Google Scholar
• Koutroubakis I. E., Malliaraki N., Dimoulios P. D., Karmiris K., Castanas E., Kouroumalis E. A. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig. Dis. Sci. 2004; 49: 1433–1437
   PubMed Web of Science ®Google Scholar
• Krawisz J. E., Sharon P., Stenson W. F. Qualitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984; 87: 1344–1350
   PubMed Web of Science ®Google Scholar
• Kruidenier L., Kuiper I., Van Duijn W., Mieremet-Ooms M. A., van Hogezand R. A., Lamers C. B., Verspaget H. W. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J. Pathol. 2003; 201: 17–27
   PubMed Web of Science ®Google Scholar
• Kvietys P. R., Inauen W., Bacon B. R., Grisham M. B. Xanthine oxidase-induced injury to endothelium: role of intracellular iron and hydroxyl radical. Am. J. Physiol. 1989; 257: H1640–1646
   PubMedGoogle Scholar
• Langtry H. D., Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs. Rev. 1999; 57: 967–989
   PubMed Web of Science ®Google Scholar
• Lih-Brody L., Powell S. R., Collier K. P., Reddy G. M., Cerchia R., Kahn E., Weissman G. S., Katz S., Floyd R. A., McKinley M. J., Fisher S. E., Mullin G. E. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig. Dis. Sci. 1996; 41: 2078–2086
   PubMed Web of Science ®Google Scholar
• Lindsey I., George B., Kettlewell M., Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis. Colon Rectum 2002; 45: 727–732
   PubMed Web of Science ®Google Scholar
• MacPherson B., Pfeiffer C. J. Experimental colitis. Digestion 1976; 14: 424–452
   PubMed Web of Science ®Google Scholar
• McKenzie S. J., Baker M. S., Buffinton G. D., Doe W. F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 1996; 98: 136–141
   PubMed Web of Science ®Google Scholar
• Milani E., Nikfar S., Khorasani R., Zamani M. J., Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 2005; 140: 251–255
   PubMed Web of Science ®Google Scholar
• Muzaffar S., Shukla N., Lobo C., Angelini G. D., Jeremy J. Y. Iloprost inhibits superoxide formation and gp91phox expression induced by the thromboxane A2 analogue U46619, 8-isoprostane F2alpha, prostaglandin F2alpha, cytokines and endotoxin in the pig pulmonary artery. Br. J. Pharmacol. 2004; 141: 488–496
   PubMed Web of Science ®Google Scholar
• Nielsen O. H., Ahnfelt-Ronne I. Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease. Klin. Wochenschr. Rev. 1991; 69: 995–1000
   PubMedGoogle Scholar
• Noronha-Blob L., Lowe V. C., Muhlhauser R. O., Burch R. M. NPC 15669, an inhibitor of neutrophil recruitment, is efficacious in acetic acid-induced colitis in rats. Gastroenterology 1993; 104: 1021–1029
   PubMed Web of Science ®Google Scholar
• Podolsky D. K. Inflammatory bowel disease. N. Engl. J. Med. Rev. 2002; 347: 417–429
   PubMed Web of Science ®Google Scholar
• Radfar M., Larijani B., Hadjibabaie M., Rajabipour B., Mojtahedi A., Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacoth. 2005; 59: 302–306
   PubMed Web of Science ®Google Scholar
• Rezaie A., Taghavi B., Abdollahi M. Biologic management of fistulizing Crohn's disease. Intl. J. Pharmacol. 2005; 1: 17–24
   Google Scholar
• Rosen R. C., Kostis J. B. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol. Rev. 2003; 92: 9M–18M
   PubMed Web of Science ®Google Scholar
• Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume. Med. J. 1998; 45: 69–73
   PubMedGoogle Scholar
• Satho K. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin. Chem. Acta. 1978; 90: 37–43
   PubMed Web of Science ®Google Scholar
• Sharon P., Stenson W. F. Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenterology 1985; 88: 55–63
   PubMed Web of Science ®Google Scholar
• Shukla N., Jones R., Persad R., Angelini G. D., Jeremy J. Y. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation inhypercholesterolaemic rabbits. Eur. J. Pharmacol. 2005; 517: 224–231
   PubMed Web of Science ®Google Scholar
• Simmonds N. J., Millar A. D., Blake D. R., Rampton D. S. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 1999; 13: 363–372
   PubMed Web of Science ®Google Scholar
• Soderling S. H., Beavo J. A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell. Biol. Rev. 2000; 12: 174–179
   PubMed Web of Science ®Google Scholar
• Souness J. E., Aldous D., Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol. Rev. 2000; 47: 127–162
   PubMed Web of Science ®Google Scholar
• Tuzun A., Erdil A., Inal V., Aydin A., Bagci S., Yesilova Z., Sayal A., Karaeren N., Dagalp K. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin. Biochem. 2002; 35: 569–572
   PubMed Web of Science ®Google Scholar
• Wakefield A. J., Sankey E. A., Dhillon A. P., Sawyerr A. M., More L., Sim R., Pittilo R. M., Rowles P. M., Hudson M., Lewis A. A. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100: 1279–1287, Erratum in Gastroenterology 101:595
   PubMed Web of Science ®Google Scholar
• Zamani M. J., Sharifzadeh M., Rezaie A., Mashayekhi F., Abdollahi M. Effects of sildenafil on rat irritable bowel syndrome. Therapy 2005; 2: 237–242
   Google Scholar